deferoxamine has been researched along with Dyskeratosis Congenita, X-Linked in 1 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pancytopenia is difficult to manage in patients with this disorder." | 1.32 | Treatment of dyskeratosis congenita with granulocyte-macrophage colony-stimulating factor and erythropoietin. ( Erduran, E; Hacisalihoglu, S; Ozoran, Y, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Erduran, E | 1 |
| Hacisalihoglu, S | 1 |
| Ozoran, Y | 1 |
1 other study available for deferoxamine and Dyskeratosis Congenita, X-Linked
| Article | Year |
|---|---|
Treatment of dyskeratosis congenita with granulocyte-macrophage colony-stimulating factor and erythropoietin.
Topics: Blood Cell Count; Bone Marrow; Child, Preschool; Deferoxamine; Disease Susceptibility; Dyskeratosis | 2003 |